牛牛AI助理已提取核心訊息
On February 23, 2024, Pfizer Inc. (Pfizer) and its wholly-owned subsidiary Pfizer Investment Enterprises Pte. Ltd. (Pfizer Singapore) filed a registration statement with the U.S. Securities and Exchange Commission (SEC) for the issuance of various securities, including debt securities, common stock, preferred stock, warrants, depositary shares, purchase contracts, and purchase units. The registration statement allows for the sale of these securities from time to time in one or more offerings. The securities may be offered at fixed prices, prevailing market prices, or negotiated prices, and may be sold through underwriters, dealers, agents, directly to purchasers, or through a combination of these methods. The registration statement also includes provisions for the indemnification of directors and officers, and outlines the potential anti-takeover effects of Pfizer's corporate governance documents and Delaware law. The specific terms of any offering, including the names of any underwriters and the compensation provided to them, will be detailed in future prospectus supplements filed with the SEC.
On February 23, 2024, Pfizer Inc. (Pfizer) and its wholly-owned subsidiary Pfizer Investment Enterprises Pte. Ltd. (Pfizer Singapore) filed a registration statement with the U.S. Securities and Exchange Commission (SEC) for the issuance of various securities, including debt securities, common stock, preferred stock, warrants, depositary shares, purchase contracts, and purchase units. The registration statement allows for the sale of these securities from time to time in one or more offerings. The securities may be offered at fixed prices, prevailing market prices, or negotiated prices, and may be sold through underwriters, dealers, agents, directly to purchasers, or through a combination of these methods. The registration statement also includes provisions for the indemnification of directors and officers, and outlines the potential anti-takeover effects of Pfizer's corporate governance documents and Delaware law. The specific terms of any offering, including the names of any underwriters and the compensation provided to them, will be detailed in future prospectus supplements filed with the SEC.
2024年2月23日，輝瑞公司（Pfizer）及其全資子公司輝瑞投資企業私人有限公司Ltd.（新加坡輝瑞）向美國證券交易委員會（SEC）提交了發行各種證券的註冊聲明，包括債務證券、普通股、優先股、認股權證、存托股票、購買合約和購買單位。註冊聲明允許不時通過一次或多次發行出售這些證券。證券可以按固定價格、現行市場價格或協議價格發行，可以通過承銷商、交易商、代理商出售，直接出售給買方，也可以通過這些方法的組合出售。註冊聲明還包括對董事和高級管理人員進行賠償的條款，並概述了輝瑞公司治理文件和特拉華州法律的潛在反收購影響。未來向美國證券交易委員會提交的招股說明書補充文件將詳細說明任何發行的具體條款，包括任何承銷商的姓名和向他們提供的補償。
2024年2月23日，輝瑞公司（Pfizer）及其全資子公司輝瑞投資企業私人有限公司Ltd.（新加坡輝瑞）向美國證券交易委員會（SEC）提交了發行各種證券的註冊聲明，包括債務證券、普通股、優先股、認股權證、存托股票、購買合約和購買單位。註冊聲明允許不時通過一次或多次發行出售這些證券。證券可以按固定價格、現行市場價格或協議價格發行，可以通過承銷商、交易商、代理商出售，直接出售給買方，也可以通過這些方法的組合出售。註冊聲明還包括對董事和高級管理人員進行賠償的條款，並概述了輝瑞公司治理文件和特拉華州法律的潛在反收購影響。未來向美國證券交易委員會提交的招股說明書補充文件將詳細說明任何發行的具體條款，包括任何承銷商的姓名和向他們提供的補償。
有用
沒用